Moreover, we showed that treatment of LRRK2-mutant flies with fingolimod, a drug that is currently being used to treat multiple sclerosis, ameliorates their disease-associated phenotypes but otherwise has no apparent effects on the climbing performance of control flies. The gene discussed is LRRK2; the disease is multiple sclerosis.